Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
Search results
The latest research news from Retina UK.
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
Skydiving is an exhilarating experience, and you can do this while supporting our cause. Various dates and locations are available across the UK.
With various events to choose from in 2026, these hugely popular events are back for another year! Round up your friends, family members and colleagues and join #TeamRetinaUK for a fun day out!
With various events to choose from in 2026, these hugely popular events are back for another year! Round up your friends, family members and colleagues and join #TeamRetinaUK for a fun day out in 2026.
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Join Stuart Copeland at Woburn Golf Club during the 50th anniversary years of both Retina UK and Woburn Golf Club.